Completed
Expert Centers Have Markedly Better SRT Outcomes But Access to Specialty Centers Are Limited
Class Central Classrooms beta
YouTube videos curated by Class Central.
Classroom Contents
Current and Evolving Understanding in Hypertrophic Cardiomyopathy - Cardiology Grand Rounds
Automatically move to the next video in the Classroom when playback concludes
- 1 Current and Evolving Understanding in Hypertrophic Cardiomyopa
- 2 Hypertrophic Cardiomyopathy: Some simple math
- 3 Step 1: Multimodality imaging key in diagnosing HCM
- 4 Recognition of Apical aneurysms
- 5 LV Strain
- 6 NIH Sponsored HCMR Registry
- 7 Machine learning. LV shape and insights into pathophysiology
- 8 AI, EKG, HCM
- 9 Machine learning and HCM
- 10 Elicit LVOT Obstruction: Don't look, Won't find, Can't Tre
- 11 Stress Echo
- 12 Recognize typical and atypical variants of obstructive HC OCM without the H: Abnormal mitral subvalvular morphology
- 13 3 different flavors of "Atypical" LVOT obstruction
- 14 Differential diagnosis using multimodality imaging
- 15 Important to make the correct diagnosis
- 16 SCD risk stratification
- 17 Comparison of ESC vs. American Approach
- 18 ICD placement
- 19 HCM LGE Outcomes
- 20 Screening Echo vs. CMR in G+P-patients
- 21 Management in oHCM
- 22 Lifestyle considerations
- 23 Vigorous exercise and HCM: LIVE-HCM Trial
- 24 In oHCM, there are no prospective RCT (single or multicenter) compar a various FDA-approved medical therapies b invasive therapies vs. FDA-approved medical Rx c myectomy vs. alcohol ablation
- 25 Septal Reduction Therapy: One operation does not fit
- 26 Cleveland Clinic approach to Surgical LVOT obstructi
- 27 Alcohol septal ablation
- 28 Guidelines: Invasive therapies
- 29 Spectrum of oHCM management in USA
- 30 Expert Centers Have Markedly Better SRT Outcomes But Access to Specialty Centers Are Limited
- 31 Mavacamten Prevents Disease Phenotype in HCM Mice
- 32 Phase III RCTs: Testing Mavacamten vs. Placebo EXPLORER-HCM vs. VALOR-HCM
- 33 Mavacamten LTE study
- 34 Valor-HCM: 92% NYHA Class III 19 US HCM Centers
- 35 Primary endpoint and NYHA Class Improvement
- 36 Secondary Efficacy Endpoints
- 37 Favorable Cardiac Remodeling
- 38 A VALOR Mavacamten Story
- 39 LVEF and mavacamten: Implications in clinical practice
- 40 Clinical management of Camzyos (Mavacamten)
- 41 Gene-therapy: Adeno-associated Virus mediated
- 42 These new therapies are going to bring new logistic scenarios, assum long-term safety and efficacy
- 43 Symptomatic Nonobstructive HCM
- 44 Managing Arrhythmias Atrial fibrillation: A Bad Actor in HCM, especially oHCM
- 45 Management of AF
- 46 Genetic Testing in HCM
- 47 Genetics and long-term outcomes: SHARE registry!
- 48 Screening of asymptomatic first-degree relativ EKG and echo
- 49 Valsartan in Early Stage HCM: VANISH Trial
